Pioneers in chemical safety assessment
Hiring Les demonstrates our commitment to continued leadership in developing and promoting new approach methods.
DURHAM, N.C. (PRWEB)
April 28, 2022
ScitoVation is pleased to announce Leslie Recio, PhD, DABT, as the new Chief Scientific Officer. Dr. Recio was the Chief Scientific Officer and Director of the Genetic and Molecular Toxicology group at ILS. Dr. Recio will help lead the team of Senior Scientists, drive priorities in New Approach Methods and help secure new business ventures.
Dr. Recio has over 30 years of experience in toxicology research in the areas of mutagenesis, toxicogenomics, and regulatory genotoxicity assessments. His research program has included studies using primary and immortalized rodent and human cell lines, transgenic rodent models, and molecular genetic approaches to examine mechanisms and identify biomarkers of cytotoxicity, genotoxicity, and mutagenicity at the molecular, cellular, and animal level. His research program focused on mode-of-action and the development of data useful for benchmark dose analysis to derive point of departure estimates used in risk assessments. More recently Dr. Recio has been committed to developing New Approach Methods to replace or reduce the reliance on animal testing by developing genotoxicity assessments in human hepatocyte models. In collaboration with MIT (Dr. Bevin Engelward) and U of Ottawa (Dr. Carole Yauk), he developed a human-relevant genotoxicity testing platform using metabolically competent human hepatocytes integrated with rapid detection of genotoxicity and mode-of-action based genomic profiling.
Dr. Recio is pleased to join ScitoVation and focus more on New Approach Methods. He explained, “I am very excited to become part of the ScitoVation team known for its scientific excellence and to lead ScitoVation in developing new alternative methodologies (NAM) to reduce, refine and replace the use of animals in toxicology with non-animal human-relevant biological systems. At ScitoVation we have a unique team with the skill sets to integrate NAMs with computational dosimetry tools to derive accurate risk assessments without the use of animals.”
The Scitovation team is pleased to have Dr. Recio on board. Dr. Jean (Sammy) Orelien, CEO at ScitoVation, shared that Dr. Recio joining the team raises ScitoVation’s visibility as a pioneer in New Approach Methods. “Hiring Les demonstrates our commitment to continued leadership in developing and promoting new approach methods. I am also looking forward to working with him.”
Dr. Recio officially began his new role on April 18th, 2022.
Additional Background on Dr. Recio:
Dr. Recio obtained his B.S. in Microbiology and M.S. and Ph.D. in Toxicology from the University of Kentucky and has been Diplomat of the American Board of Toxicology (DABT) since 1998. Dr Recio is internationally recognized for his expertise in regulatory genetic toxicology, research in genetic and molecular toxicology and mode-of-action assessment using genomic technologies. He has served on the Organization for Economic Cooperation and Development (OECD) Genetic Toxicology Expert Working Group since 2014. Dr. Recio was the Principal Investigator for the National Toxicology Program (NTP) genetic toxicology testing for more than 17 yrs. In this role, Dr. Recio oversaw genotoxicity assessments of NTP test compounds in a battery of genetic toxicology assays following international regulatory testing guidelines.
Dr. Recio was appointed to the editorial boards of Mutagenesis, Toxicological Sciences and Mutation Research Reviews. He was appointed as an Associate Editor for Toxicological Sciences from 2016-2019. He is a member of several scientific societies, including the Environmental Mutagen Society, the Society of Toxicology, and the Genetics and Environmental Mutagenesis Society, and has served several elected leadership positions, including GEMS President, President of the SOT Hispanic Organization of Toxicologists special interest group, and Council Member for the North Carolina Chapter of the Society of Toxicology.
About ScitoVation:
ScitoVation helps clients develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals, and consumer products using innovative science and next generation technology. The company is known for partnership, flexibility, and proven success in assisting clients to address safety and effectiveness for both internal stakeholders and regulators. Recognized as industry experts in the use of New Approach Methods (NAMs), the team pioneered cell-based and computational methods to provide leading-edge solutions with results that are scientifically sound and withstand scrutiny, including from peer-reviewers and regulators.
Share article on social media or email: